18h • GLP-1 & Weight Loss
Hot off the press... New Reta Study Released
🔹 Who was in this trial?
Adults who were obese or overweight and had knee osteoarthritis – so not a general population weight-loss study.
🔹 Dosing details
Participants started at 2 mg once weekly and increased every 4 weeks until hitting 9 mg or 12 mg.
These new results are based on those high doses (9–12 mg).
More data is expected in 2026, including info on the planned 4 mg maintenance dose.
🔹 Weight loss: Retatrutide vs Tirzepatide
- Retatrutide 12 mg: ~28.7% average body-weight reduction at 68 weeks
- For reference - Tirzepatide (Zepbound) max dose: ~21–22% average weight loss at 72 weeks
So yes, Retta is looking very powerful on the scale.
🔹 Side effects & discontinuations
- Adverse-event–related discontinuations:
- Dysesthesia (skin/nerve sensitivity)
🫀 Heart rate note:
This particular trial summary didn’t mention heart rate changes at all — which is interesting, because when I tried a very low “micro” dose of Retta transitioning off tirzepatide, I personally noticed an increased resting heart rate, and with my anxiety that was a no-go.
Everyone’s nervous system and tolerance is different — and Retatrutide is still investigational, not FDA approved.
📌 Education only, not medical advice.
I’m a coach and educator, not a prescriber. Always work with a licensed provider before starting or changing any medication.
1
2 comments
Hot off the press... New Reta Study Released
powered by
skool.com/glp-1-peptide-clarity-group-5837
Optimize your body from the inside out — learn how peptides, GLP-1s & lifestyle strategies restore balance, energy & lasting vitality.
Suggested communities
Powered by